If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
132
results.
Updated on
30/04/2025 [06:58:00]
Results 25 to 50 of 132
Absstract of: US2025120618A1
A non-invasive blood glucose monitoring module with high optical transmittance includes a substrate, a first detecting unit and a second detecting unit. The first detecting unit includes a first light source set, a first photosensitive element and first blocking wall structures. The first photosensitive element receives light, with a first wavelength, emitted from the first light source set. The first blocking wall structures are located between the two first light-emitting elements and between the first light source set and the first photosensitive element. The second detecting unit includes a second light source set, a second photosensitive element and second blocking wall structures. The second photosensitive element receives light, with a second wavelength, emitted from the second light source set. The second blocking wall structures are located between the two second light-emitting elements and between the second light source set and the second photosensitive element.
Absstract of: AU2025202313A1
The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal-only dosing of insulin. In a primary embodiment, the wearable drug delivery device is configured to provide automatic operation and provides audible alerts and visual status indicators to the patient. In other embodiments, the patient may have some degree of control over the operation of the device by providing tapping gestures on housing of the device. In yet another embodiment, the patient may provide input and receive status from the device via an application executing on a portable computing device in wireless communication with the wearable drug delivery device.
Absstract of: WO2025079745A1
The present invention provides a novel method for providing power to an insulin pump in order to facilitate the full return of a diabetic patient to normal daily life. The present invention includes: an insulin pump that is connected inside the body and administers insulin; and a portable battery pack that can provide power to the insulin pump by coming into contact with one side of the insulin pump. The insulin pump comprises: an injection unit for injecting insulin into the body: a first battery unit that stores power for operating the insulin pump and can be repeatedly charged and discharged; an operation unit, provided on a portion of one surface of the insulin pump, for operating the insulin pump; a first charging unit provided on a portion of the one surface of the insulin pump and connected to the first battery unit in contact with the portable battery pack in order to provide power; and a control unit for controlling the injection unit, the first battery unit, and the operation unit. The portable battery pack comprises: a second battery unit that can charge the first battery unit by using the stored power; and a second charging unit that comes into contact with the first charging unit in order to charge the first battery unit.
Absstract of: WO2025079746A1
The present invention relates to an insulin pump, which is a medical device for diabetic patients, and to a system for providing a safety device for preventing an accident that may occur when an insulin syringe for supplying insulin to the insulin pump is replaced. An insulin syringe replacement system for an insulin pump provided by the present invention comprises: a control unit for controlling the operation of the insulin pump; an operation unit for performing an initialization setting operation when an insulin syringe is replaced under the control of the control unit; and a battery unit for supplying power to the control unit and the operation unit; a housing unit for mounting the insulin syringe; and a sensor unit for confirming whether a stopper of the insulin syringe mounted on the housing unit is coupled and notifying the control unit of the confirmation, wherein the control unit controls the operation unit to perform the initialization setting operation only after receiving the confirmation from the sensor unit that the stopper of the insulin syringe mounted on the housing unit is coupled.
Absstract of: WO2025076843A1
An insulin needle tip protection mechanism and an insulin injection device. According to the insulin needle tip protection mechanism, by means of the cooperation of a U-shaped reciprocating groove (3) and an elastic wall (6), a needle tip can be automatically retracted after injection, and cannot be pushed out again, so that the purpose of needle tip protection is achieved, and secondary use can also be avoided.
Absstract of: WO2025076766A1
A method for searching for a lost device, applied to a diabetes management system. The diabetes management system comprises at least one wearable medical device, at least one personal management device and one secondary management device, wherein at least one of the personal management device and the secondary management device can be used to control the wearable medical device, and the personal management device is in communication connection with the secondary management device; and when one of the personal management device and the secondary management device is identified as lost, the lost device is searched for by means of the other one of the personal management device and the secondary management device, such that a user can easily find the lost device.
Absstract of: AU2023379646A1
Systems, devices and methods are provided for titration of a medication dose for a patient or user. The titration may be based on determining a hypoglycemic risk of a user for a plurality of time-of-day periods. The determination of the hypoglycemic risk may be accomplished by known methods, including the glucose pattern analysis, glucose dysregulation analysis, low alarm frequency analysis, and combinations thereof. The system may then select a recommended action based on the analyte pattern type. The system may then store an indicator of the recommended action in a computer memory for output. The system may then output the recommended action. The recommended action may be outputted to the user, an HCP, or a caregiver. The recommended action may also vary depending on who is receiving the recommended action.
Absstract of: WO2025081104A1
Disclosed herein are system, method, and computer program product embodiments for analyzing the impact of personal choices on future glucose levels. The disclosed techniques assess the consequences of decisions involving diet and exercise on future glucose levels using trained models and display personally relatable, intuitive, and modifiable visualizations of predicted future glucose levels. The disclosed interface allows the user to adjust the sequencing of these decisions and portion sizes of meal choices and immediately visualize the impact on predicted future glucose levels. The interface seamlessly integrates with partner systems and with wearable fitness devices.
Absstract of: US2025121213A1
A dialysis-ultrasound system is described that includes an ultrasound therapy device integrated with a catheter to incorporate ultrasound therapy into a dialysis system. The ultrasound device may be or may include a high-intensity focused ultrasound (HIFU) device or peripheral focused ultrasound stimulation (pFUS) device. The ultrasound therapy may target the liver, for example, to treat diabetes. In one example, a system includes a catheter configured to be arranged within the peritoneal cavity of a patient for peritoneal dialysis (PD), and an ultrasound device configured to emit ultrasound waves. The ultrasound device is integrated with the catheter and is arranged on the catheter to be implanted within the peritoneal cavity of the patient to provide ultrasound therapy to a target region of the patient. Other embodiments are described.
Absstract of: US2025120616A1
Embodiments relate to a non-enzymatic glucose sensor. The non-enzymatic glucose sensor comprises one or more electrodes, a microfluidic channel, and at least one inlet, wherein the at least one inlet is configured to deliver a fluid to a microfluidic channel and wherein the microfluidic channel is configured to transport the fluid to the one or more electrodes. At least one of the one or more electrodes is a laser-induced graphene electrode, wherein the laser-induced graphene electrode comprises one or more uniform coatings of metal.
Absstract of: GB2634673A
A sensor 100 for extracting and detecting an analyte (e.g. glucose, hormones, toxins, biomarkers) from a subject comprises at least one co-monitoring sensor pixel 110, a substrate 102 for positioning on the subject’s skin 200, and a set of electrodes 112. The substrate has at least one reservoir 108. The set of electrodes includes extraction electrodes for iontophoretic extraction of the analyte and a reference substance into the reservoir, target detection electrodes for detecting the amount of analyte in the reservoir, and reference detection electrodes for detecting the amount of reference substance in the reservoirs. Analyte concentration may be estimated by receiving a signal corresponding to the amount of analyte extracted into the sensor reservoir through a set of dermal channels 204 (e.g. hair follicles or microneedles), and determining the number of dermal channels in the set. Analyte flux through a selected number of dermal channels is determined based on the signal and dermal channel number . A reference flux of the reference substance through the selected number of dermal channels at a reference concentration is obtained (e.g. from a look-up table), and analyte concentration estimated based on analyte flux, reference flux and reference concentration.
Absstract of: EP4537751A1
A blood glucose measurement device having a display, includes a housing having one or more openings on one side, one or more contact electrodes configured to electrically coupled to a sensor strip inserted into the housing through the one or more openings, one or more control buttons configured to turn on the blood glucose measurement device, and one or more processors configured to control a first execution screen to be displayed in response to receiving a first signal by the one or more contact electrodes and, display a second execution screen in response to receiving a second signal by the one or more control buttons.
Absstract of: EP4537752A1
The invention provides a manufacturing method for a non-invasive blood glucose monitoring device, which comprises the following steps: providing a substrate; performing an injection molding process or an electroplating process, to form at least one light-blocking wall on the substrate, wherein each light-blocking wall includes a lower wall-structure and an upper wall-structure, and the lower wall-structure connects the substrate and the upper wall-structure connects the lower wall-structure; arranging a light-emitting element and a light-receiving element on the substrate and separating the light-emitting element and the light-receiving element by the at least one light-blocking wall; forming a packaging structure on the substrate in which the light-emitting element and the light-receiving element are packaged; and disposing a transparent cover on the packaging structure and the at least one light-blocking wall and limiting the transparent cover to a configuration height by the at least one light-blocking wall.
Absstract of: US2025116625A1
An analyte sensor includes a microcontroller, a base layer, a conductive layer disposed on the base layer where the conductive layer includes a working electrode configured to provide a current signal in presence of glucose, an interference rejection membrane (“IRM”) layer disposed on the working electrode where the IRM layer is negatively charged, and an enzyme layer disposed on the IRM layer where the enzyme layer includes an enzyme selected to generate a detectable electrical signal upon exposure to the glucose. The microcontroller is configured to process an electrochemical impedance spectroscopy (EIS) parameter to determine a state of the IRM layer.
Absstract of: US2025114385A1
An organic glucose beverage and a novel glucose monitoring system are provided that significantly improves process of diabetes screening, diagnosis, and treatment of hypoglycemia including gestational diabetes mellitus (GDM), type-1 diabetes, type-2 diabetes, and hypoglycemia. The organic glucose beverage comprises organic glucose in form of dextrose monohydrate, juice concentrates, citric acid, and water. The organic glucose beverage is provided in the form of a ready-to-drink beverage. The glucose monitoring system comprises an organic glucose beverage, a device for blood sugar monitoring, and a device for the determination of a predefined threshold value. The present invention provides first time an organic beverage for gestational diabetes mellitus (GDM), type-1 diabetes, type-2 diabetes, and hypoglycemia. The organic glucose beverage of the present invention is healthier, well tolerated, and does not include artificial flavors, dyes, or toxic preservatives which sets it apart from conventional glucose solutions for use in diabetes screening and diagnosis.
Absstract of: US2025114275A1
The present invention relates to an insulin bottle insulator and protection device. The device is comprised of a body, an interior space, and a cooling element. The device is further comprised of a lid that keeps the cold air in the device. The interior space is further comprised of an interior protection sleeve that protects the insulin bottle from breaks and cracks if dropped. The device further allows the user to be able to transport their insulin bottles without the risk of being broken or becoming unusable because they become too warm.
Absstract of: WO2025074375A1
Disclosed herein is a system (100) and method (500) to form a continuous glucose monitoring (CGM) device The system (100) includes a modular housing (106) that has a display unit (102). The system (100) further includes a continuous glucose monitoring (CGM) patch (112) that is removably disposed within the modular housing (106) and communicably coupled to the display unit (102). The CGM patch (112) detects a glucose content of a user. The display unit (102) outputs the detected glucose content of the user for a first period. Based on a completion of the first period, the CGM patch (112) is removed from the modular housing (106).
Absstract of: US2025114023A1
Provided is a method for producing a biosignal measurement electrode including: preparing a conductive polymer including a coil-type chain structure having a coil shape; providing a sugar alcohol and a water-soluble polymer to the conductive polymer to produce an electrode source including an expanded chain structure in which the coil-type chain structure is expanded and linearly arranged; forming a coating layer by providing the electrode source on a substrate; and producing the biosignal measurement electrode by annealing the coating layer.
Absstract of: GB2634417A
A botulinum toxin syringe having a barrel has volumetric marking graduations scaled at four units per 0.1 mL. These volumetric marking graduations allow for ease of unit conversion and can reduce the likelihood of overdosing or under dosing of botulinum toxin. The syringe may further comprise further volumetric marking graduations configured to be interchangeably used for administration of insulin or botulinum toxin. The syringe may further comprise further volumetric marking graduations configured for interchangeably use for administration of different types of botulinum toxin.
Absstract of: AU2023280320A1
Certain aspects provide a monitoring system comprising a continuous analyte sensor configured to generate analyte measurements associated with analyte levels of a patient, and a sensor electronics module coupled to the continuous analyte sensor and configured to receive and process the analyte measurements.
Absstract of: US2022323676A1
A computer-implemented diabetes management method includes a first determination of an insulin bolus related to one or more obtained glucose values and optionally the expected carbohydrate content of a meal to be ingested, a re-calculation of an insulin bolus in consideration of a user's body parameter information as measured by a body-worn sensor, providing a notification to the user if there is a significant deviation between the two calculated bolus amounts, and a user input whether the calculated insulin bolus or the re-calculated insulin bolus is selected by the user for bolus administration.
Absstract of: US2025107729A1
Blood glucose monitoring is a difficult task that people with diabetes often have to perform on their own. Accurate and timely prediction is vital for making decisions and recommending corrective actions. Therefore, there is a need to develop effective and accurate glucose prediction methods that allow the development of safe blood glucose monitoring systems using simple and convenient devices for the patient.The present invention describes a non-invasive method and system for the prediction of glucose values, based on the estimation from variables measured with an activity wristband. The system uses variables that are not directly related to glucose to estimate and predict glucose values and generates alerts to dangerous situations of hypoglycemia and hyperglycemia.
Absstract of: US2025108165A1
Embodiments of the present disclosure relate to approaches for more efficiently measuring glucose levels using a wearable drug delivery device. In some embodiments, the wearable drug delivery device may include a needle deployment component including a cannula and an optical conduit deployable into a user, the cannula operable to deliver a liquid drug to the user. The wearable drug delivery device may further include a glucose monitor including an optical sensor, the optical sensor operable to measure a light output received via the optical conduit.
Absstract of: US2025108150A1
This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.
Nº publicación: WO2025072927A1 03/04/2025
Applicant:
TANDEM DIABETES CARE INC [US]
TANDEM DIABETES CARE, INC
Absstract of: WO2025072927A1
Systems and methods are provided including insulin pump systems for determining certain information about a user of a wearable insulin pump based on naturally spoken user data by applying the user data to a large language model (LLM) or other machine learning model to parse the user data into categories. For example, certain rules and/or constraints may be provided to the LLM and may cause the LLM or machine learning model to parse the user data into defined categories that may be used for updating a user record. Categories may include food consumption, activities, sleep, and/or pump operation information, for example. Additional data may be determined from the parsed data such as caloric information, exercise duration, sleep information and the like. The parsed categorized data and/or additional data may be used to adjust operation of the insulin delivery pump.
BOPI
Electronic site
